On Thursday, Kronos Bio Inc (KRON) stock saw a decline, ending the day at $0.92 which represents a decrease of $-0.03 or -3.16% from the prior close of $0.95. The stock opened at $0.95 and touched a ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Kronos Bio ( (KRON) ) has shared an update.

We recently compiled a list of the 10 Biggest Dividend Cuts and Suspensions of 2024. In this article, we are going to take a ...

This high-end mobile home by Titan Vans packs a variety of niceties, including a well-equipped kitchen, a comfy bed, and a spacious seating area.

We recently compiled a list of the 11 Best Small Cap Chemical Stocks to Buy According to Hedge Funds. In this article, we are ...

Kronos Q324 sales volumes soared, offsetting flat TiO2 selling prices to deliver +22% YoY revenue growth along with improved profitability. The company faces high growth expectations as it ...

"The payment of our cash dividend reflects our confidence in the company’s growth trajectory and our ability to reward the trust of our investors," said Greg Rubin, CEO. "As we continue to innovate ...

The restructuring comes weeks after the San Mateo biotech shelved its sole drug in clinical trials, a cancer drug called istisociclib, after patients experienced various neurological side effects.

Kronos Bio has announced the appointment of Deborah Knobelman as president and interim chief executive officer, effective from 3 December 2024. Dr Knobelman will also become principal executive ...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics to address cancers and other diseases ...

Kronos Bio, Inc. (NASDAQ:KRON) shares are trading higher on Wednesday in the premarket session. The firm announced significant leadership and operational changes. Deborah Knobelman has been ...

Kronos Bio, Inc.已终止与Genentech, Inc.和F. Hoffmann-La Roche Ltd的合作，有效取消了自2023年1月6日以来一直存在的重要定义协议。这次终止于2024年12月20日发生，并通过过渡协议和相互一般性解除协议正式确定。